The mixed-lineage leukemia 1 (MLL1) gene (now renamed Lysine [K]-specific
MethylTransferase 2A or KMT2A) on chromosome 11q23 is disrupted in a unique group of …

Although significant improvements have been made in the outcomes of children with cancer,
the pace of improvement has slowed in recent years as the limits of therapy intensification …

Overall survival (OS) of pediatric patients with acute myeloid leukemia (AML) increased in
recent decades. However, it remained unknown whether advances in first-line treatment …

Background Although pediatric cancer mortality and survival have improved in the United
States over the past 40 years, differences exist by age, race/ethnicity, cancer site, and …

JCM | Free Full-Text | Pediatric Acute Myeloid Leukemia—Past, Present, and Future Next
Article in Journal Sexual Habits and Sexual Dysfunctions in a Sample of Patients with Psychotic …

Pediatric acute myeloid leukemia is a rare and heterogeneous disease in relation to
morphology, immunophenotyping, germline and somatic cytogenetic and genetic …

Pediatric acute myeloid leukemia (AML) represents 15%–20% of all pediatric acute
leukemias. Survival rates have increased over the past few decades to~ 70%, due to …

New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce
disease recurrence and treatment-related morbidity. The Children's Oncology Group Phase …

Abstract Treatment outcomes for pediatric patients with acute myeloid leukemia (AML) have
continued to lag behind outcomes reported for children with acute lymphoblastic leukemia …

Further incorporation of genomic and molecular data in pediatric AML will allow for
additional refinements in risk stratification to enable the tailoring of treatment intensity. These …